Nurix Therapeutics, Inc. (NRIX)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

1700 OWENS STREET, SUITE 205 SAN FRANCISCO, CA 94158

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.

Data as of 2021-09-11 12:03:04 -0400
Market Cap1.59 Billion Shares Outstanding44.427 Million Avg 30-day Volume289.296 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS0
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE5.74 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.14667 52-week High/Low52.38 / 21.53 Next Earnings Date2021-10-13 Price to Cash FLow (P/CF) -44.6022
Data provided by IEX Cloud
View SEC Filings from NRIX instead.

View recent insider trading info

Funds Holding NRIX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NRIX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

16.3 Thousand total shares from 10 transactions

Exercise Derivative Conversion (M)

16.3 Thousand total shares from 7 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

RING CHRISTINE GENERAL COUNSEL

  • Officer
106,952 2021-09-10 11

HANSEN GWENN CHIEF SCIENTIFIC OFFICER

  • Officer
83,663 2021-09-07 13

WOLFF STEFANI EVP AND COO

  • Officer
0 2021-08-16 1

BEAURANG PIERRE CHIEF BUSINESS OFFICER

  • Officer
127,558 2021-08-10 9

SIEGALL CLAY B

  • Director
0 2021-05-28 2

COLUMN GROUP L P

COLUMN GROUP GP, LP

COLUMN GROUP II, LP

COLUMN GROUP II GP, LP

PONOI CAPITAL, LP

PONOI MANAGEMENT, LLC

PONOI II MANAGEMENT, LLC

PONOI CAPITAL II, LP

KUTZKEY TIM

GOEDDEL DAVID V

  • 10% Owner
  • GENERAL PARTNER
No longer subject to file 2021-05-07 1

COLUMN GROUP L P

SVENNILSON PETER

  • 10% Owner
No longer subject to file 2021-05-07 1

THIRD ROCK VENTURES III, L.P.

THIRD ROCK VENTURES GP III, L.P.

TRV GP III, LLC

STARR KEVIN P

TEPPER ROBERT I

LEVIN MARK J

  • 10% Owner
3,682,941 2021-05-06 1

GREGORY JULIA P

  • Director
17,500 2021-05-06 1

TONG JEFFREY K

  • Director
  • 10% Owner
17,500 2021-05-06 1

KUNKEL LORI ANNE

  • Director
17,500 2021-05-06 1

LACEY DAVID L.

  • Director
17,500 2021-05-06 1

CHEN LEON

  • Director
17,500 2021-05-06 1

VAN HOUTE HANS CHIEF FINANCIAL OFFICER

  • Officer
65,667 2021-02-24 4

SANDS ARTHUR T PRESIDENT, CEO

  • Officer
  • Director
0 2021-02-11 2

REDMILE GROUP, LLC

GREEN JEREMY

  • 10% Owner
No longer subject to file 2020-07-28 0

WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P.

  • 10% Owner
No longer subject to file 2020-07-28 0

TJIAN ROBERT

  • Director
124,999 2020-07-28 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

RING CHRISTINE - Officer GENERAL COUNSEL

2021-09-13 16:07:27 -0400 2021-09-10 M 2,000 d 105,666 direct yes

RING CHRISTINE - Officer GENERAL COUNSEL

2021-09-13 16:07:27 -0400 2021-09-10 S 700 $35.10 d 2,586 direct yes 1.9048 1.9048 2 0.0 1

RING CHRISTINE - Officer GENERAL COUNSEL

2021-09-13 16:07:27 -0400 2021-09-10 S 800 $36.76 d 1,286 direct yes 1.9048 1.9048 2 0.0 1

RING CHRISTINE - Officer GENERAL COUNSEL

2021-09-13 16:07:27 -0400 2021-09-10 M 2,000 $1.86 a 3,286 direct yes 1.9048 1.9048 2 0.0 1

RING CHRISTINE - Officer GENERAL COUNSEL

2021-09-13 16:07:27 -0400 2021-09-10 S 500 $35.77 d 2,086 direct yes 1.9048 1.9048 2 0.0 1

HANSEN GWENN - Officer CHIEF SCIENTIFIC OFFICER

2021-09-08 17:08:09 -0400 2021-09-07 S 1,600 $35.00 d 14,197 direct yes -2.4257 -2.5075 0.0 1 -2.6983 4

RING CHRISTINE - Officer GENERAL COUNSEL

2021-09-08 17:08:54 -0400 2021-09-07 S 3,200 $35.25 d 1,286 direct yes -2.4257 -2.5075 0.0 1 -2.6983 4

HANSEN GWENN - Officer CHIEF SCIENTIFIC OFFICER

2021-09-08 17:08:09 -0400 2021-09-07 M 1,600 $7.26 a 15,797 direct yes -2.4257 -2.5075 0.0 1 -2.6983 4

RING CHRISTINE - Officer GENERAL COUNSEL

2021-09-08 17:08:54 -0400 2021-09-07 M 3,200 $1.86 a 4,486 direct yes -2.4257 -2.5075 0.0 1 -2.6983 4

HANSEN GWENN - Officer CHIEF SCIENTIFIC OFFICER

2021-09-08 17:08:09 -0400 2021-09-07 M 1,600 d 69,466 direct yes

RING CHRISTINE - Officer GENERAL COUNSEL

2021-09-08 17:08:54 -0400 2021-09-07 M 3,200 d 107,666 direct yes

HANSEN GWENN - Officer CHIEF SCIENTIFIC OFFICER

2021-09-02 16:22:50 -0400 2021-09-01 S 400 $32.34 d 14,197 direct yes 6.2745 8.5973 10.6787 4 0.0 1

HANSEN GWENN - Officer CHIEF SCIENTIFIC OFFICER

2021-09-02 16:22:50 -0400 2021-09-01 M 400 $7.26 a 14,597 direct yes 6.2745 8.5973 10.6787 4 0.0 1

HANSEN GWENN - Officer CHIEF SCIENTIFIC OFFICER

2021-09-02 16:22:50 -0400 2021-09-01 M 400 d 71,066 direct yes

BEAURANG PIERRE - Officer CHIEF BUSINESS OFFICER

2021-08-11 18:20:52 -0400 2021-08-10 S 1,880 $30.21 d 4,330 direct yes -2.6557 -6.1966 0.0 1 -6.5128 3

RING CHRISTINE - Officer GENERAL COUNSEL

2021-08-11 18:21:45 -0400 2021-08-10 M 1,200 d 110,866 direct yes

BEAURANG PIERRE - Officer CHIEF BUSINESS OFFICER

2021-08-11 18:20:52 -0400 2021-08-10 S 5,620 $29.74 d 6,210 direct yes -2.6557 -6.1966 0.0 1 -6.5128 3

RING CHRISTINE - Officer GENERAL COUNSEL

2021-08-11 18:21:45 -0400 2021-08-10 S 1,200 $29.87 d 805 direct yes -2.6557 -6.1966 0.0 1 -6.5128 3

BEAURANG PIERRE - Officer CHIEF BUSINESS OFFICER

2021-08-11 18:20:52 -0400 2021-08-10 M 7,500 d 6,562 direct yes

BEAURANG PIERRE - Officer CHIEF BUSINESS OFFICER

2021-08-11 18:20:52 -0400 2021-08-10 M 7,500 $1.11 a 11,830 direct yes -2.6557 -6.1966 0.0 1 -6.5128 3

RING CHRISTINE - Officer GENERAL COUNSEL

2021-08-11 18:21:45 -0400 2021-08-10 M 1,200 $1.86 a 2,005 direct yes -2.6557 -6.1966 0.0 1 -6.5128 3

HANSEN GWENN - Officer CHIEF SCIENTIFIC OFFICER

2021-08-03 17:39:41 -0400 2021-08-02 M 400 $7.26 a 14,204 direct yes -1.9265 -9.1879 6.0166 8.7433 26 -12.3592 9

HANSEN GWENN - Officer CHIEF SCIENTIFIC OFFICER

2021-08-03 17:39:41 -0400 2021-08-02 M 400 d 71,466 direct yes

HANSEN GWENN - Officer CHIEF SCIENTIFIC OFFICER

2021-08-03 17:39:41 -0400 2021-08-02 S 400 $31.21 d 13,804 direct yes -1.9265 -9.1879 6.0166 8.7433 26 -12.3592 9

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
NURIX THERAPEUTICS INC NRIX 2021-09-17 22:15:03 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 21:45:03 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 21:15:04 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 20:45:03 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 20:15:05 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 19:45:03 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 19:15:03 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 18:45:03 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 18:15:03 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 17:45:03 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 17:15:03 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 16:45:03 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 16:15:02 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 15:45:02 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 15:15:03 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 14:45:03 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 14:15:03 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 13:45:02 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 13:15:03 UTC -0.3598 0.4298 400000
NURIX THERAPEUTICS INC NRIX 2021-09-17 12:45:03 UTC -0.3598 0.4298 400000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund NRIX -200.0 shares, $-5306.0 2021-06-30 N-PORT

Elevate your investments